A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

Episodic migraine is a diagnosis applied to patients with migraine who experience 1-14 headache days per month. CGRP (calcitonin gene-related peptide) is a neuropeptide that has been implicated in the pathophysiology of migraine. The study drug in this trial, AGN-241689, is a CGRP receptor antagonist being developed for migraine prevention. The objective of this study is to assess the safety, tolerability and efficacy of AGN-241689 compared with placebo in the prevention of episodic migraine.

Primary Sponsor:
Allergan

Prinicipal Investigator:
John Rothrock, MD/Neurology

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):